Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Cancer Communications

Fig. 2

From: Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

Fig. 2

Characteristics of neck lymph node regression in patients with nasopharyngeal carcinoma receiving famitinib and concurrent chemoradiotherapy. The response was measured as the largest percentage reduction in the sum of the longest diameters of target lesions for all assessable patients with a radiographic assessment (n = 20). Response kinetics in patients receiving famitinib a 12.5 or b 16.5 or c 20 or d 25 mg cohort and all the patients (e). Tumours were assessed 2 weeks after taking famitinib (D15), at the end of CCRT and 12 weeks after treatment according to the RECIST (version 1.0) guidelines; horizontal line at − 30% marks the threshold for defining objective response (partial tumour regression) according to RECIST, and a horizontal line at − 20% indicates the threshold for defining progressive disease. f Waterfall plot of best tumour response 2 weeks after taking famitinib (D15). *Indicated that two lines overlapped together

Back to article page